Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment – oxaliplatin subscale: A prospective cohort study

Current chemotherapy-induced peripheral neuropathy (CIPN) assessment tools mostly have poor sensitivity and weak anti-interference, so that it is sometimes difficult to provide substantive guidance for clinical intervention. This study aimed to develop an assessment tool dedicated for oxaliplatin to address these limitations.